Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health

被引：28

作者：

Noia Maciel, Ethel Leonor ^{[1
]}

Guidoni, Leticia Molino

Favero, Juliana Lopes

Hadad, David Jamil

Molino, Lucilia Pereira ^{[2
]}

Jonhson, John L. ^{[3
,4
]}

Dietze, Reynaldo

机构：

[1] Univ Fed Espirito Santo, Ctr Ciencias Saude, Nucleo Doencas Infecciosas, BR-29040091 Vitoria, ES, Brazil

[2] Hosp Univ Cassiano Antonio Moraes, Pesquisa Clin, Med Ctr, Vitoria, ES, Brazil

[3] Case Western Reserve Univ, Sch Med, Dept Med, TB Res Unit, Cleveland, OH 44106 USA

[4] Univ Hosp Case Med Ctr, Cleveland, OH USA

来源：

JORNAL BRASILEIRO DE PNEUMOLOGIA | 2010年 / 36卷 / 02期

关键词：

Treatment outcome; Tuberculosis; Antitubercular agents; Adverse drug reaction reporting systems; ANTITUBERCULOSIS DRUGS; RISK-FACTORS; RIFAMPIN; PYRAZINAMIDE; HEPATITIS; HEPATOTOXICITY;

D O I：

10.1590/S1806-37132010000200012

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Objective: To determine the principal adverse effects of the tuberculosis treatment regimen recommended by the Brazilian Ministry of Health. Methods: A prospective descriptive study involving 79 tuberculosis patients treated at the Clinical Research Center of the Cassiano Antonio Moraes University Hospital, in the city of Vitoria, Brazil, between 2003 and 2006 The treatment regimen consisted of isoniazid, rifampicin, pyrazinamide and ethambutol for four months, followed by rifampicin and isoniazid for two months. During the treatment period, the patients were clinically evaluated every week and had a monthly medical visit. Results: The overall incidence of adverse effects was 83.54%. Articular/bone/muscle involvement was the most common, followed by skin involvement (24.94% and 22.09%, respectively). Adverse effects were more common in the second month of treatment (41.59%). Modification of the treatment regimen was unnecessary One patient required concomitant medication to counter the adverse effects. The cure rate was 100%. Conclusions: The overall incidence of adverse effects related to the new treatment regimen recommended by the Brazilian Ministry of Health was high However, none of those effects demanded a change in the regimen, which was effective in the patients evaluated.

引用

页码：232 / 238

页数：7

共 24 条

[1]

[Anonymous], PORT SAUD

[2]

Bartacek A, 2009, INT J TUBERC LUNG D, V13, P760

[3]

Bisaglia J. B., 2003, B PNEUMOLOGIA SANITA, V11, P53

[4]

*BRAS MIN SAUD SEC, 2002, 6 BRAS MIN SAUD DEP

[5] Adverse events and treatment interruption in tuberculosis patients with and without HIV coinfection [J].

Breen, R. A. M. ;

Miller, R. F. ;

Gorsuch, T. ;

Smith, C. J. ;

Schwenk, A. ;

Holmes, W. ;

Ballinger, J. ;

Swaden, L. ;

Johnson, M. A. ;

Cropley, I. ;

Lipman, M. C. .

THORAX, 2006, 61 (09) :791-794

[6] DELETERIOUS INFLUENCE OF PYRAZINAMIDE ON THE OUTCOME OF PATIENTS WITH FULMINANT OR SUBFULMINANT LIVER-FAILURE DURING ANTITUBERCULOUS TREATMENT INCLUDING ISONIAZID [J].

DURAND, F ;

BERNUAU, J ;

PESSAYRE, D ;

SAMUEL, D ;

BELAICHE, J ;

DEGOTT, C ;

BISMUTH, H ;

BELGHITI, J ;

ERLINGER, S ;

RUEFF, B ;

BENHAMOU, JP .

HEPATOLOGY, 1995, 21 (04) :929-932

[7]

FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151

[8] Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture Conversion [J].

Johnson, John L. ;

Hadad, David Jamil ;

Dietze, Reynaldo ;

Noia Maciel, Ethel Leonor ;

Sewali, Barrett ;

Gitta, Phineas ;

Okwera, Alphonse ;

Mugerwa, Roy D. ;

Alcaneses, Mary Rose ;

Quelapio, Maria Imelda ;

Tupasi, Thelma E. ;

Horter, Libby ;

Debanne, Sara M. ;

Eisenach, Kathleen D. ;

Boom, W. Henry .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 180 (06) :558-563

[9]

KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991

[10]

Lee AM, 2002, INT J TUBERC LUNG D, V6, P995

← 1 2 3 →